Schedule of Segment Financial Information |
The following tables set forth financial information by segment: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended June 30, 2025 | | Consumer Products segment | | Ingredients segment | | Analytical Reference Standards and Services segment | | Corporate and other | | Total | | | | | | (In thousands) | | | | | | Net sales | | $ | 22,699 | | | $ | 7,619 | | | $ | 799 | | | $ | — | | | $ | 31,117 | | Cost of sales | | 7,453 | | | 2,808 | | | 630 | | | — | | | 10,891 | | Gross profit | | 15,246 | | | 4,811 | | | 169 | | | — | | | 20,226 | | Operating expenses: | | | | | | | | | | | | | | | | | | | | | | Sales and marketing | | | | | | | | | | | Advertising | | 2,882 | | | — | | | — | | | — | | | 2,882 | | Marketing | | 2,514 | | | 45 | | | — | | | — | | | 2,559 | | Selling | | 2,678 | | | 7 | | | 81 | | | — | | | 2,766 | | Research and development | | 1,169 | | | 398 | | | — | | | — | | | 1,567 | | General and administrative | | — | | | — | | | — | | | 7,267 | | | 7,267 | | Operating expenses | | 9,243 | | | 450 | | | 81 | | | 7,267 | | | 17,041 | | | | | | | | | | | | | Operating income (loss) | | $ | 6,003 | | | $ | 4,361 | | | $ | 88 | | | $ | (7,267) | | | $ | 3,185 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended June 30, 2024 | | Consumer Products segment | | Ingredients segment | | Analytical Reference Standards and Services segment | | Corporate and other | | Total | | | | | | (In thousands) | | | | | | Net sales | | $ | 18,647 | | | $ | 3,301 | | | $ | 791 | | | $ | — | | | $ | 22,739 | | Cost of sales | | 6,785 | | | 1,545 | | | 716 | | | — | | | 9,046 | | Gross profit | | 11,862 | | | 1,756 | | | 75 | | | — | | | 13,693 | | Operating expenses: | | | | | | | | | | | Sales and marketing | | | | | | | | | | | | | | | | | | | | | | Advertising | | 2,548 | | | — | | | — | | | — | | | 2,548 | | Marketing | | 2,069 | | | 50 | | | 3 | | | — | | | 2,122 | | Selling | | 2,160 | | | 16 | | | 123 | | | — | | | 2,299 | | Research and development | | 1,135 | | | 181 | | | — | | | — | | | 1,316 | | General and administrative | | — | | | — | | | — | | | 5,664 | | | 5,664 | | Operating expenses | | 7,912 | | | 247 | | | 126 | | | 5,664 | | | 13,949 | | | | | | | | | | | | | Operating income (loss) | | $ | 3,950 | | | $ | 1,509 | | | $ | (51) | | | $ | (5,664) | | | $ | (256) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Six Months Ended June 30, 2025 | | Consumer Products segment | | Ingredients segment | | Analytical Reference Standards and Services segment | | Corporate and other | | Total | | | | | | (In thousands) | | | | | | Net sales | | $ | 44,200 | | | $ | 15,788 | | | $ | 1,610 | | | $ | — | | | $ | 61,598 | | Cost of sales | | 14,860 | | | 5,909 | | | 1,272 | | | — | | | 22,041 | | Gross profit | | 29,340 | | | 9,879 | | | 338 | | | — | | | 39,557 | | Operating expenses: | | | | | | | | | | | Sales and marketing | | | | | | | | | | | Advertising | | 5,858 | | | — | | | — | | | — | | | 5,858 | | Marketing | | 4,967 | | | 70 | | | — | | | — | | | 5,037 | | Selling | | 5,185 | | | 56 | | | 188 | | | — | | | 5,429 | | Research and development | | 2,081 | | | 744 | | | — | | | — | | | 2,825 | | General and administrative | | — | | | — | | | — | | | 12,451 | | | 12,451 | | Operating expenses | | 18,091 | | | 870 | | | 188 | | | 12,451 | | | 31,600 | | | | | | | | | | | | | Operating income (loss) | | $ | 11,249 | | | $ | 9,009 | | | $ | 150 | | | $ | (12,451) | | | $ | 7,957 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Six Months Ended June 30, 2024 | | Consumer Products segment | | Ingredients segment | | Analytical Reference Standards and Services segment | | Corporate and other | | Total | | | | | | (In thousands) | | | | | | Net sales | | $ | 35,998 | | | $ | 7,389 | | | $ | 1,505 | | | $ | — | | | $ | 44,892 | | Cost of sales | | 12,939 | | | 3,382 | | | 1,422 | | | — | | | 17,743 | | Gross profit | | 23,059 | | | 4,007 | | | 83 | | | — | | | 27,149 | | Operating expenses: | | | | | | | | | | | Sales and marketing | | | | | | | | | | | Advertising | | 5,035 | | | — | | | — | | | — | | | 5,035 | | Marketing | | 3,966 | | | 62 | | | 4 | | | — | | | 4,032 | | Selling | | 4,372 | | | 16 | | | 254 | | | — | | | 4,642 | | Research and development | | 2,830 | | | 581 | | | — | | | — | | | 3,411 | | General and administrative | | — | | | — | | | — | | | 11,016 | | | 11,016 | | Operating expenses | | 16,203 | | | 659 | | | 258 | | | 11,016 | | | 28,136 | | | | | | | | | | | | | Operating income (loss) | | $ | 6,856 | | | $ | 3,348 | | | $ | (175) | | | $ | (11,016) | | | $ | (987) | |
|
Schedule of Disaggregation of Revenue |
Disaggregated revenues are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, 2025 | | Consumer Products Segment | | Ingredients Segment | | Analytical Reference Standards and Services Segment | | Total | (In thousands) | | | | | Tru Niagen®, Consumer Product | | $ | 22,699 | | | $ | — | | | $ | — | | | $ | 22,699 | | Food-grade Niagen® | | — | | | 5,994 | | | — | | | 5,994 | | Pharmaceutical-grade Niagen® | | — | | | 1,390 | | | — | | | 1,390 | | Subtotal Niagen® Related | | 22,699 | | | 7,384 | | | — | | | 30,083 | | Other Ingredients | | — | | | 235 | | | — | | | 235 | | Reference Standards | | — | | | — | | | 772 | | | 772 | | Consulting and Other | | — | | | — | | | 27 | | | 27 | | Subtotal Other Goods and Services | | — | | | 235 | | | 799 | | | 1,034 | | Total Net Sales | | $ | 22,699 | | | $ | 7,619 | | | $ | 799 | | | $ | 31,117 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, 2024 | | Consumer Products Segment | | Ingredients Segment | | Analytical Reference Standards and Services Segment | | Total | (In thousands) | | | | | Tru Niagen®, Consumer Product | | $ | 18,647 | | | $ | — | | | $ | — | | | $ | 18,647 | | Food-grade Niagen® | | — | | | 3,144 | | | — | | | 3,144 | | | | | | | | | | | Subtotal Niagen® Related | | 18,647 | | | 3,144 | | | — | | | 21,791 | | Other Ingredients | | — | | | 157 | | | — | | | 157 | | Reference Standards | | — | | | — | | | 755 | | | 755 | | Consulting and Other | | — | | | — | | | 36 | | | 36 | | Subtotal Other Goods and Services | | — | | | 157 | | | 791 | | | 948 | | Total Net Sales | | $ | 18,647 | | | $ | 3,301 | | | $ | 791 | | | $ | 22,739 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | Six Months Ended June 30, 2025 | | Consumer Products Segment | | Ingredients Segment | | Analytical Reference Standards and Services Segment | | Total | (In thousands) | | | | | Tru Niagen®, Consumer Product | | $ | 44,200 | | | $ | — | | | $ | — | | | $ | 44,200 | | Food-grade Niagen® | | — | | | 12,968 | | | — | | | 12,968 | | Pharmaceutical-grade Niagen® | | — | | | 2,390 | | | — | | | 2,390 | | Subtotal Niagen® Related | | 44,200 | | | 15,358 | | | — | | | 59,558 | | Other Ingredients | | — | | | 430 | | | — | | | 430 | | Reference Standards | | — | | | — | | | 1,570 | | | 1,570 | | Consulting and Other | | — | | | — | | | 40 | | | 40 | | Subtotal Other Goods and Services | | — | | | 430 | | | 1,610 | | | 2,040 | | Total Net Sales | | $ | 44,200 | | | $ | 15,788 | | | $ | 1,610 | | | $ | 61,598 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | Six Months Ended June 30, 2024 | | Consumer Products Segment | | Ingredients Segment | | Analytical Reference Standards and Services Segment | | Total | (In thousands) | | | | | Tru Niagen®, Consumer Product | | $ | 35,998 | | | $ | — | | | $ | — | | | $ | 35,998 | | Food-grade Niagen® | | — | | | 7,232 | | | — | | | 7,232 | | | | | | | | | | | Subtotal Niagen® Related | | 35,998 | | | 7,232 | | | — | | | 43,230 | | Other Ingredients | | — | | | 157 | | | — | | | 157 | | Reference Standards | | — | | | — | | | 1,436 | | | 1,436 | | Consulting and Other | | — | | | — | | | 69 | | | 69 | | Subtotal Other Goods and Services | | — | | | 157 | | | 1,505 | | | 1,662 | | Total Net Sales | | $ | 35,998 | | | $ | 7,389 | | | $ | 1,505 | | | $ | 44,892 | |
|
Schedule of Major Customers |
Percentage of net sales from major customers of the Company’s consumer products segment and ingredients segment for the periods indicated were as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | Major Customers | | 2025 | | 2024 | | 2025 | | 2024 | A.S. Watson Group - Former Related Party (1) | | * | | 16.4 | % | | * | | 14.9 | % | Life Extension | | 10.2 | % | | * | | 12.7 | % | | 11.4 | % | | | | | | | | | | | | | | | | | | | | | | | | | | | | * Represents less than 10%(1) For additional information regarding the relationship between the Company and A.S. Watson Group, see Note 6, Related Party Transactions. The percentage of the amounts due from major customers to total trade receivables, net for the periods indicated were as follows: | | | | | | | | | | | | | | | | | Percentage of the Company's Total Trade Receivables | Major Customers | | At June 30, 2025 | | At December 31, 2024 | A.S. Watson Group - Former Related Party (1) | | 24.1 | % | | 47.6 | % | | | | | | | | | | | Amazon Marketplaces | | 12.2 | % | | 14.3 | % | Life Extension | | 22.0 | % | | * | Wells Pharma of Houston | | 13.4 | % | | 10.3 | % | | | | | | | | | | | | | | | | | | | | |
* Represents less than 10% (1) For additional information regarding the relationship between the Company and A.S. Watson Group, see Note 6, Related Party Transactions.
|